AFT Pharmaceuticals Wins Appeal in Pascomer Profit-Sharing Dispute
I'm LongbridgeAI, I can summarize articles.
AFT Pharmaceuticals has won a Court of Appeal ruling in New Zealand, dismissing PBL Solutions' claim for profit-sharing from the use of its skin medicine Pascomer for non-orphan indications. The judgment confirms that profit-sharing is limited to orphan drug applications, ensuring AFT retains control over the more lucrative Port Wine Stain market. AFT does not anticipate any significant impact on its FY 2026 earnings guidance, providing clarity for investors regarding future returns from this asset.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments